Company Overview

Viridian Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing potential best‑in‑class therapies for serious and rare diseases. The company operates within the biopharmaceutical and rare disease therapeutics industries, with a strategic concentration on immune‑mediated and fibrotic disorders. Its primary value proposition centers on advancing targeted biologic therapies designed to address conditions with limited or no approved treatment options.

Viridian’s core pipeline is focused on thyroid eye disease (TED), an autoimmune condition associated with Graves’ disease. The company’s lead product candidates are monoclonal antibodies targeting the insulin‑like growth factor‑1 receptor (IGF‑1R), intended to improve efficacy, safety, and dosing convenience relative to existing therapies. Viridian was founded in 2013 and initially pursued oncology indications before strategically refocusing on rare immunological diseases, culminating in its current emphasis on TED following internal pipeline reprioritization and asset development.

Business Operations

Viridian operates as a single reporting segment focused on the research and development of biologic therapies. Its primary revenue‑generating activities are currently limited, as the company does not have approved commercial products and relies on capital raised through equity offerings to fund operations. Research and development activities represent the majority of operating expenses and are directed toward advancing clinical trials for its TED pipeline candidates.

The company’s lead programs include VRDN‑001, an intravenously administered anti‑IGF‑1R monoclonal antibody, and VRDN‑003, a subcutaneous formulation designed to offer more convenient administration. Viridian conducts its development activities through a combination of internal scientific teams and outsourced clinical research organizations, with manufacturing supported by third‑party contract manufacturers. Based on publicly available disclosures, the company does not report material operating subsidiaries or joint ventures and primarily manages operations directly at the parent‑company level.

Strategic Position & Investments

Viridian’s strategic direction is centered on establishing a differentiated position in the TED treatment landscape by improving dosing, safety, and patient experience compared to existing therapies. Growth initiatives are focused on advancing late‑stage clinical development, expanding clinical datasets to support regulatory approval, and exploring lifecycle management opportunities for its core IGF‑1R antibody platform.

The company has made targeted investments in expanding its clinical and regulatory capabilities to support potential commercialization. Rather than pursuing broad diversification, Viridian has concentrated capital allocation on its TED franchise, reflecting a strategy of depth over breadth. As of the most recent publicly available filings, the company has not disclosed significant acquisitions of other companies, and its pipeline assets have been developed primarily through internal research and in‑licensing of foundational technologies. Data inconclusive based on available public sources regarding additional undisclosed portfolio investments.

Geographic Footprint

Viridian Therapeutics is headquartered in the United States, with its principal executive offices located in Massachusetts. The company’s operational footprint is primarily U.S.‑based, reflecting its status as a clinical‑stage biotechnology firm without commercial manufacturing or sales infrastructure.

International presence is largely limited to clinical trial activities conducted across North America and Europe, where patient enrollment and investigator sites support its development programs. While Viridian does not maintain significant physical operations outside the U.S., its regulatory strategy and clinical development plans indicate an intention to pursue approvals in multiple global markets, subject to trial outcomes and regulatory review.

Leadership & Governance

Viridian is led by an executive team with experience in biotechnology development, clinical strategy, and capital markets. The leadership emphasizes disciplined capital allocation, scientific rigor, and a focused approach to rare disease drug development, particularly in areas with clear unmet medical need and regulatory pathways.

Key members of the leadership team include:

• Stephen Mahoney – President and Chief Executive Officer
• Scott Myers, M.D. – Chief Medical Officer

The company is governed by a board of directors composed of industry executives and investors with backgrounds in biotechnology, finance, and corporate governance, providing oversight aligned with shareholder interests and long‑term value creation.